Drug Profile
Autologous cultured chondrocytes - Vericel
Alternative Names: Articel; Autologous cultured chondrocytes on porcine collagen membrane; MACI; MACI Implant; Matrix-applied-characterised-autologous-cultured-chondrocytes-Vericel; Matrix-induced autologous chondrocyte implantLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Verigen AG
- Developer Vericel Corporation
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Knee injuries
- Phase II Osteonecrosis
Most Recent Events
- 08 Mar 2024 Withdrawn for Knee injuries in Australia (Parenteral) (Vericel Corporation SEC filing, Form 10-K, March 2024)
- 29 Feb 2024 Vericel Corporation plans the commercial launch of MACI Arthroscopic in the third quarter of 2024
- 29 Feb 2024 Vericel Corporation plans a clinical trial for Cartilage defects in the ankle in 2025